+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibody Drug Conjugates Market by Indication, Linker, Payload, Target Antigens and Geography: Industry Trends and Global Forecasts, 2021-2030

  • PDF Icon


  • 630 Pages
  • August 2021
  • Region: Global
  • Roots Analysis
  • ID: 5450182


Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies. ADCs are engineered therapeutics comprised of monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers. In fact, the FDA has approved 11 ADCs, namely ado-trastuzumab emtansine (Kadcyla®), brentuximab vedotin (Adcetris®), inotuzumab ozogamicin (Besponsa®), gemtuzumab ozogamicin (Mylotarg®), moxetumomab pasudotox (Lumoxiti®), polatuzumab vedotin-piiq (Polivy®), enfortumab vedotin (Padcev®), sacituzumab govitecan (Trodelvy®), trastuzumab deruxtecan (Enhertu®), belantamab mafodotin-blmf (Blenrep®), and loncastuximab tesirine-lpyl (Zynlonta™) till date. The success of these therapeutics can be attributed to their high tumor selectivity and cell-killing potential of monoclonal antibodies, while limiting off target toxicities. These advantages have made ADCs a new frontier of chemotherapy, thus, bringing about a paradigm shift in the treatment protocol of different types of cancer.

The growing popularity of ADCs is evident from the number of patents filed / granted for ADCs, which has increased from 1,992 in 2011 to over 22,700 in the first quarter of 2021. With approximately 80 ADCs being investigated in more than 250 clinical trials, the pharmaceutical industry is witnessing a dynamic shift from conventional technologies to newer and more robust approaches for the development of such complex biomolecules. In the past few years, several well-funded start-ups / small companies, offering advanced linker technologies, more potent warheads, and novel conjugation technologies, were established. Moreover, multiple licensing deals were inked in the past few years between various stakeholders, to advance the development of ADCs product pipeline. It is worth noting that companies are also evaluating their proprietary ADCs in combination with other effective therapeutic modalities, such as epigenetic modulator, immune checkpoint inhibitors, and monoclonal antibodies. ADC-based combination therapies offer multifaceted advantages, such as reduced drug resistance, improved drug efficacy, shrinking tumor metastasis, and increased cancer survival rates. In addition, novel conjugated drug molecules, such as bicycle drug conjugate (Bicycle Therapeutics), extracellular drug conjugate (Centrose), peptide conjugate (Esperance Pharmaceuticals), phospholipid drug conjugate (Cellectar Biosciences), radionucleotide conjugate (Nordic Nanovector), and tunable drug conjugate (BlinkBio) have also been introduced. Driven by the substantial progress in the use of novel ADC-based combination therapies, the associated clinical results, and ongoing technological advancement, coupled to the marketing authorization of multiple ADCs, the ADC therapeutics market is anticipated to grow at a commendable rate in the mid to long-term.

Scope of the Report

The “Antibody Drug Conjugates Market (6th Edition) by Target Indication (Breast cancer, Blood cancer, Colorectal cancer, Gastric cancer, Gynecological cancer, Head and neck cancer, Lung cancer, and Others), Type of Linker Used (VC, Sulfo-SPDB, VA, Hydrazone linker, and Others), Type of Payload (MMAE, DM4, Camptothecin, DM1, MMAF, and Others), Target Antigens (CD30, HER2, CD22, CD33, and Others), and Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current and future potential of ADCs being developed for the treatment of various indications. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade.

Amongst other elements, the report includes:

  • A detailed review of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, phase III, phase II/III, phase II, phase I/II, phase I, preclinical / discovery stage) of lead candidates, target antigen (CD30, HER2, CD22, CD33, and Others), type of linker used (VC, Sulfo-SPDB, VA, Hydrazone linker, and Others), type of payload / warhead / cytotoxin (MMAE, DM4, Camptothecin, DM1, MMAF, and Others), type of antibody (Anti-HER2, Anti-TROP2, Anti-CD30, Anti-mesothelin, Anti-CD22, and Others), antibody isotype (IgG, IgG1, IgG2, and IgG4), type of therapy (monotherapy and combination therapy), combination drug(s) (if being evaluated as combination therapy), target indication(s) (breast cancer, blood cancer, colorectal cancer, gastric cancer, gynecological cancer, head and neck cancer, lung cancer, and others), line of treatment (1st line, 2nd line, 3rd line, and Others), route of administration (intravenous and subcutaneous), and dosing frequency (Q1 weeks, Q2 weeks, Q3 weeks, Q4 weeks, and Others).
  • Elaborate profiles of companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments, and an informed future outlook.
  • An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
  • A list of key opinion leaders (KOLs) within this domain, featuring detailed 2×2 matrices to assess the relative experience of the individuals, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. In addition, it presents an analysis assessing the credibility and (relative) level of expertise of different KOLs, based on number of publications, number of citations, number of clinical trials, number of affiliations, and strength of professional network (based on information available on LinkedIn).
  • An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved in drug development efforts based on a singular target and geographical distribution of associated clinical trials. 
  • An analysis of the recent collaborations (since 2014) focused on the development of ADCs. It includes partnerships inked by various stakeholders in this domain, covering R&D collaborations, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, mergers and acquisitions, and other relevant agreements. 
  • An analysis of the investments made, including seed funding, venture capital financing, debt funding, grants, capital raised from IPOs and subsequent offerings, at various stages of development, in companies that are focused on developing ADCs.
  • An in-depth analysis of the various patents that have been filed / granted related to ADCs. It includes information on key parameters, such as patent type, publication year, geographical location, issuing authority, assigned CPC symbol, emerging focus areas, and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2016 and 2021, highlighting various important parameters, such as year of award, support period, amount awarded, funding institute, grant type, focus area, type of recipient organization, key project leaders, key regions, and leading recipient organizations.
  • An in-depth analysis of completed, ongoing, and planned clinical studies of various ADCs, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication, and key geographical regions.
  • An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch, including a timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products.
  • An analysis of the key promotional strategies that have been adopted by the developers of marketed products, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA® and ADCETRIS®.
  • An assessment of various therapeutics that are being evaluated in combination with ADCs. The study also presents the likely evolution of these therapeutics across different indications. 
  • A review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations; in addition, it presents a review of the existing competition between various conjugation approaches that are available / under development.
  • An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs. The study presents findings from various ADC studies in different animal models. It also includes an analysis of different methods used in estimating FIH doses. In addition, it highlights the possible FIH starting doses and estimated dose escalations required to reach human maximum tolerated dose (MTD).
  • An elaborate discussion on various factors that form the basis for the pricing of ADC products, featuring different models / approaches that pharmaceutical companies may choose to adopt while deciding the price of their respective lead therapy candidates that are likely to be marketed in the coming years.
  • A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain.
  • A case study on companies offering companion diagnostics that can potentially be used to make treatment related decisions involving ADCs, providing information on the geographical location of key diagnostic developers, affiliated disease biomarkers, assay technique involved, target indication(s), the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidates for which a particular test was developed.
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

Key Questions Answered

  • Who are the leading players engaged in the development of ADCs?
  • Which indications can be treated with ADCs?
  • Which partnership models are commonly adopted by stakeholders in this domain?
  • What are the investment trends in this industry?
  • Which are the most active clinical trial centers?
  • Who are the key opinion leaders that can help you drive your development efforts?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Table of Contents

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

3.1. Chapter Overview
3.2. Evolution of Anticancer Therapies
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies
3.4. Monoclonal Antibody-Based Anticancer Therapies
3.5. Components of Antibody Drug Conjugates (ADCs)
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Linker
3.6. Advantages of ADC Therapeutics Over Traditional Therapeutic Interventions
3.7. Differences Between Small Molecule Drugs, Monoclonal Antibody-Based Therapies and ADCs
3.8. Pharmacokinetic Properties of ADCs
3.8.1. Absorption
3.8.2. Distribution
3.8.3. Metabolism and Elimination

4.1. Chapter Overview
4.2. Antibody Drug Conjugates: Drug Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Target Disease Indication
4.2.3. Analysis by Line of Treatment
4.2.4. Analysis by Dosing Regimen
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Target Antigen
4.2.7. Analysis by Antibody Origin
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Type of Linker
4.2.10. Analysis by Type of Payload / Warhead
4.2.11. Antibody Drug Conjugates: Distribution by Target Antigens and Target Disease Indications
4.2.12. Antibody Drug Conjugates Approved and Development Pipeline: Grid Analysis
4.3. Antibody Drug Conjugates: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Key Players: Analysis by Number of Therapies
4.3.5. Logo Landscape: Analysis by Target Disease Indication and Company Size
4.3.6. Technology Platforms
4.4. Novel Drug Conjugates

5.1. Chapter Overview
5.2. Seagen
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Pipeline Overview Adcetris Padcev HuMax-TF SGN-LIVIA
5.2.4. Recent Developments and Future Outlook
5.3. Roche / Genentech
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Pipeline Overview Kadcyla Polivy
5.3.4. Recent Developments and Future Outlook
5.4. Pfizer
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Pipeline Overview Mylotarg Besponsa
5.4.4. Recent Developments and Future Outlook
5.5. AstraZeneca
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Pipeline Overview Enhertu
5.5.4. Recent Developments and Future Outlook
5.6. Astellas Pharma
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Pipeline Overview
5.6.4. Recent Developments and Future Outlook
5.7. ImmunoGen
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Pipeline Overview Mirvetuximab Soravtansine
5.7.4. Recent Developments and Future Outlook
5.8. Daiichi Sankyo
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Pipeline Overview Patritumab deruxtecan Datopotamab deruxtecan
5.8.4. Recent Developments and Future Outlook
5.9. Gilead
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Pipeline Overview Trodelvy
5.9.4. Recent Developments and Future Outlook
5.10. AbbVie
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Pipeline Overview Telisotuzumab vedotin ABBV-3373
5.10.4. Recent Developments and Future Outlook
5.11. Bayer
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Pipeline Overview Anetumab ravtansine
5.11.4. Recent Developments and Future Outlook
5.12. RemeGen
5.12.1. Company Overview
5.12.2. Pipeline Overview Disitamab vedotin
5.12.3. Recent Developments and Future Outlook
5.13. ADC Therapeutics
5.13.1. Company Overview
5.13.2. Pipeline Overview Zynlonta Camidanlumab tesirine
5.13.3. Recent Developments and Future Outlook

6.1. Chapter Overview
6.2. Hematological Malignancies
6.2.1. Leukemias and Lymphomas Leukemia: Introduction and Epidemiology Acute Myeloid Leukemia Chronic Myeloid Leukemia Acute Lymphocytic Leukemia Chronic Lymphocytic Leukemia Lymphoma: Introduction and Epidemiology Current Treatment Landscape Targeted Therapies ADC Therapeutics for Leukemia / Lymphoma
6.2.2. Multiple Myeloma Introduction and Epidemiology Current Treatment Landscape ADC Therapeutics for Multiple Myeloma
6.3. Solid Tumors
6.3.1. Lung Cancer Introduction and Epidemiology Current Treatment Landscape ADC Therapeutics for Lung Cancer
6.3.2. Breast Cancer Introduction and Epidemiology Current Treatment Landscape ADC Therapeutics for Breast Cancer
6.3.3. Ovarian Cancer Introduction and Epidemiology Current Treatment Landscape ADC Therapeutics for Ovarian Cancer
6.3.4. Bladder Cancer Introduction and Epidemiology Current Treatment Landscape ADC Therapeutics for Bladder Cancer
6.3.5. Colorectal Cancer Introduction and Epidemiology Current Treatment Landscape ADC Therapeutics for Colorectal Cancer
6.3.6. Prostate Cancer Introduction and Epidemiology Current Treatment Landscape ADC Therapeutics for Prostate Cancer
6.3.7. Gastric Cancer Introduction and Epidemiology Current Treatment Landscape ADC Therapeutics for Gastric Cancer

7.1. Chapter Overview
7.2. Methodology
7.3. Principal Investigators Involved in Clinical Trials
7.3.1. Geographical Distribution of Key Opinion Leaders Experts on Adcetris Experts on Kadcyla Experts on Mylotarg Experts on Other ADCs
7.4. Prominent Key Opinion Leaders (KOLs)
7.5. KOL Benchmarking: Publisher versus Third Party Scoring
7.6. Most Active Key Opinion Leaders
7.6.1. KOL Profile: KOL A (Celgene)
7.6.2. KOL Profile: KOL B (Georgetown University and Medical centre)
7.6.3. KOL Profile: KOL C (Cancer Hospital and Institute)
7.6.4. KOL Profile: KOL D (Comprehensive Cancer Centers of Nevada)

8.1. Chapter Overview
8.2. Key Parameters
8.3. Methodology
8.4. Competitiveness Analysis: Key Clinical Targets for ADCs
8.4.1. Four-Dimensional Bubble Analysis
8.4.2. Five-Dimensional Spider Web Analysis

9.1. Chapter Overview
9.2. Partnership Models
9.3. Antibody Drug Conjugates: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Regional Analysis Intercontinental and Intracontinental Agreements

10.1. Chapter Overview
10.2. Types of Funding
10.3. Antibody Drug Conjugates: Funding and Investment Analysis
10.3.1. Analysis by Year of Investment
10.3.2. Analysis by Number of Funding Instances
10.3.3. Analysis by Amount Invested
10.3.4. High Value Deals: Analysis by Year of Investment
10.3.5. Analysis by Type of Funding
10.3.6. Most Active Players Analysis by Number of Funding Instances Analysis by Amount Invested
10.3.7. Most Active Investors: Analysis by Number of Instances
10.4. Concluding Remarks

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Antibody Drug Conjugates: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Geography
11.3.3. Analysis by CPC Symbols
11.3.4. Emerging Focus Areas
11.3.5. Analysis by Type of Organization
11.3.6. Leading Players: Analysis by Number of Patents
11.4. Antibody Drug Conjugates: Benchmarking Patent Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Antibody Drug Conjugates: Patent Valuation Analysis

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Antibody Drug Conjugates: List of Academic Grants
12.3.1. Analysis by Year of Grant Award
12.3.2. Analysis by Grant Amount Awarded
12.3.3. Analysis by Administering Institute Center
12.3.4. Analysis by Support Period
12.3.5. Analysis by Funding Institute Center and Support Period
12.3.6. Analysis by Type of Grant Application
12.3.7. Analysis by Purpose of Grant Award
12.3.8. Analysis by Activity Code
12.3.9. Emerging Focus Areas
12.3.10. Analysis by Study Section Involved
12.3.11. Popular NIH Departments: Analysis by Number of Grants
12.3.12. Analysis by Type of Recipient Organization
12.3.13. Prominent Program Officers: Analysis by Number of Grants
12.3.14. Popular Recipient Organizations: Analysis by Number of Grants
12.3.15. Regional Distribution of Recipient Organizations

13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Antibody Drug Conjugates: Clinical Trial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Phase
13.3.3. Analysis by Trial Recruitment Status
13.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
13.3.5. Analysis by Study Design
13.3.6. Analysis by Sponsor / Collaborator
13.3.7. Most Active Players: Analysis by Number of Registered Trials
13.3.8. Emerging Focus Areas
13.3.9. Analysis by Trial Phase and Target Disease Indication
13.3.10. Geographical Analysis by Number of Clinical Trials
13.3.11. Geographical Analysis by Number of Patients Enrolled

14.1. Chapter Overview
14.2. Successful Drug Launch Strategy: Publisher Framework
14.3. Successful Drug Launch Strategy: Product Differentiation
14.4. Common Commercialization Strategies Adopted Based on Development Stage of Product
14.5. Approved ADCs: An Overview
14.5.1. Adcetris
14.5.2. Kadcyla
14.5.3. Mylotarg
14.5.4. Besponsa
14.5.5. Lumoxity
14.5.6. Polivy
14.6. Key Commercialization Strategies Adopted by the Companies Developing Antibody Drug Conjugates
14.6.1. Strategies Adopted Before the Approval of Drug Participation in Global Events Adcetris Kadcyla Mylotarg Besponsa Lumoxiti Polivy Collaboration with External Stakeholders and Pharmaceutical Firms Adcetris Kadcyla
14.6.2. Strategies Adopted During / Post Approval of Drug Geographical Expansion Adcetris Kadcyla Besponsa Participation in Global Events Post Product Approval Adcetris Kadcyla Mylotarg Besponsa Lumoxiti Awareness Through Product Websites Collaboration with External Stakeholders and Pharmaceutical Firms Adcetris Lumoxiti
14.7. Concluding Remarks

15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website Analysis
15.4. Summary of Patient Brochure and Informative Downloads
15.5. Adcetris: Promotional Analysis
15.5.1. Product Website Analysis Messages for Healthcare Professionals Messages for Patients
15.5.2. Patient Support Services and Informative Downloads
15.5.3. Other Promotional Activities Participation in Conferences
15.6. Kadcyla: Promotional Analysis
15.6.1. Product Website Analysis Messages for Healthcare Professionals Messages for Patients
15.6.2. Patient Support Services and Informative Downloads
15.6.3. Other Promotional Activities Participation in Conferences
15.7. Mylotarg: Promotional Analysis
15.7.1. Product Website Analysis Messages for Healthcare Professionals Messages for Patients
15.7.2. Patient Support Services and Informative Downloads
15.7.3. Other Promotional Activities Participation in Conferences
15.8. Besponsa: Promotional Analysis
15.8.1. Product Website Analysis Messages for Healthcare Professionals Messages for Patients
15.8.2. Patient Support Services and Informative Downloads
15.8.3. Other Promotional Activities Participation in Conferences
15.9. Lumoxiti: Promotional Analysis
15.9.1. Product Website Analysis Messages for Healthcare Professionals Messages for Patients
15.9.2. Patient Support Services and Informative Downloads
15.9.3. Other Promotional Activities Participation in Conferences
15.10. Polivy: Promotional Analysis
15.10.1. Product Website Analysis Messages for Healthcare Professionals Messages for Patients
15.10.2. Patient Support Services and Informative Downloads
15.10.3. Other Promotional Activities Participation in Conferences

16.1. Chapter Overview
16.2. Combination Therapy: History of Development
16.3. Combination Therapy: FDA Guidelines
16.3.1. Combinations of Marketed Drugs
16.3.2. Combinations of Marketed Drugs with New Molecular Entities
16.3.3. Combinations of New Molecular Entities
16.4. Combination Therapies: ADCs
16.4.1. Completed / Ongoing Clinical Studies of ADCs Analysis by Type of Therapy
16.4.2. Completed / Ongoing Clinical Studies of ADC-Based Combination Therapies Analysis by Highest Phase of Development Analysis by Current Trial Status Analysis by Type of Combination Therapy Analysis by Target Disease Indication and Type of Combination Therapy

17.1. Chapter Overview
17.2. First Generation ADC Technologies
17.3. Second Generation ADC Technologies
17.3.1. Cysteine and Selenocysteine Engineering
17.3.2. Unnatural Amino Acid Engineering
17.3.3. Amino-Terminal Serine Engineering
17.4. Third Generation ADC Technologies
17.4.1. Enzyme-Assisted Ligation Approaches
17.4.2. Glycan Remodeling Approaches
17.4.3. Ligation at Fab Nucleotide-Binding Site
17.4.4. Cysteine Rebridging
17.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
17.5. Other Emerging ADC Technologies
17.6. Evolutionary Analysis

18.1. Chapter Overview
18.2. ADCs and Non-Clinical Studies
18.3. ICH S9 Guidelines
18.4. Investigational New Drug (IND)-Enabling Study Designs
18.4.1. Example Case: Kadcyla
18.5. Toxicities in Animal Models
18.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
18.7. Other Key Considerations for Study Design

19.1. Chapter Overview
19.2. Factors Contributing Towards the High Price of Antibody Drug Conjugates
19.3. Antibody Drug Conjugates Market: Pricing Models
19.3.1. On the Basis of Associated Costs
19.3.2. On the Basis of Competition
19.3.3. On the Basis of Patient Segment
19.4. Reimbursement Considerations for Antibody Drug Conjugates

20.1. Chapter Overview
20.2. Key Steps for ADC Manufacturing
20.3. Technical Challenges Associated with ADC Manufacturing
20.4. Challenges Associated with Supply Chain and Method Transfer
20.5. Limitations of In-House Manufacturing
20.6. Investments in ADC Manufacturing Capability Expansions
20.7. Collaborations Established for ADC Manufacturing
20.8. Growing Demand for ADC Contract Manufacturing
20.9. Emergence of Start-Ups Offering Contract Services
20.10. CMOs with Linker Manufacturing Capabilities
20.11. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
20.12. CMOs with Conjugation Capabilities
20.13. ADC One-stop-shops

21.1. Chapter Overview
21.1.1. Advantages of Companion Diagnostics
21.1.2. Challenges Associated with the Development of Companion Diagnostics
21.2. Companion Diagnostics for ADC Therapeutics
21.3. Other Companion Diagnostics
21.3.1. Analysis by Type of Target Antigen
21.3.2. Analysis by Type of Cancer
21.4. Most Active Players: Analysis by Number of Companion Diagnostics Developed

22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats

23.1. Chapter Overview
23.2. Scope and Limitations
23.3. Forecast Methodology
23.4. Overall Antibody Drug Conjugates Market
23.4.1. Antibody Drug Conjugates Market: Distribution by Target Disease Indication
23.4.2. Antibody Drug Conjugates Market: Distribution by Type of Linker
23.4.3. Antibody Drug Conjugates Market: Distribution by Type of Payload
23.4.4. Antibody Drug Conjugates Market: Distribution by Target Antigen
23.4.5. Antibody Drug Conjugates Market: Distribution by Geography
23.5. Antibody Drug Conjugates Market: Individual Drug Sales Forecasts
23.5.1. Adcetris Target Patient Population Sales Forecast
23.5.2. Kadcyla Target Patient Population Sales Forecast
23.5.3. Mylotarg Target Patient Population Sales Forecast
23.5.4. Besponsa Target Patient Population Sales Forecast
23.5.5. Lumoxiti Target Patient Population Sales Forecast
23.5.6. Polivy Target Patient Population Sales Forecast
23.5.7. Trodelvy Target Patient Population Sales Forecast
23.5.8. Enhertu Target Patient Population Sales Forecast
23.5.9. Zynlonta Target Patient Population Sales Forecast
23.5.10. Blenrep Target Patient Population Sales Forecast
23.5.11. Padcev Target Patient Population Sales Forecast
23.5.12. Tisotumab vedotin Target Patient Population Sales Forecast
23.5.13. Mirvetuximab soravtansine Target Patient Population Sales Forecast
23.5.14. ABBV-3373 Target Patient Population Sales Forecast
23.5.15. Anetumab ravtansine Target Patient Population Sales Forecast
23.5.16. Disitamab vedotin Target Patient Population Sales Forecast
23.5.17. MRG002 Target Patient Population Sales Forecast
23.5.18. Naratuximab emtansine Target Patient Population Sales Forecast
23.5.19. Trastuzumab duocarmazine Target Patient Population Sales Forecast
23.5.20. Tusamitamab ravtansine Target Patient Population Sales Forecast
23.5.21. Cetuximab sarotalocan Target Patient Population Sales Forecast
23.5.22. BA3011 Target Patient Population Sales Forecast

24.1. Chapter Overview
24.2. Oxford Biotherapeutics
24.2.1. Company Snapshot
24.2.2. Interview Transcript: Christian Rohlff, Founder and Chief Executive Officer
24.3. Angiex
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Paul Jaminet, Founder and Chief Executive Officer
24.4. Syndivia
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Sasha Koniev, Co-Founder and Chief Executive Officer
24.5. BSP Pharmaceuticals
24.5.1. Company Snapshot
24.5.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager
24.6. Abzena
24.6.1. Company Snapshot
24.6.2. Interview Transcript: John Burt, Chief Executive Officer
24.7. CureMeta
24.7.1. Company Snapshot
24.7.2. Interview Transcript: Michael Schopperle, Chief Executive Officer
24.8. CytomX
24.8.1. Company Snapshot
24.8.2. Interview Transcript: Jeff Landau, Chief Business Officer and Head of Strategy
24.9. NBE-Therapeutics
24.9.1. Company Snapshot
24.9.2. Interview Transcript: Wouter Verhoeven, Chief Business Officer
24.10. Cerbios-Pharma
24.10.1. Company Snapshot
24.10.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer
24.11. Eisai
24.11.1. Company Snapshot
24.11.2. Interview Transcript: Toshimitsu Uenaka, Executive Director and Takashi Owa, Chief Innovation Officer
24.12. AbTis
24.12.1. Company Snapshot
24.12.2. Interview Transcript: Justin Oh, Executive Director
24.13. AmbrX
24.13.1. Company Snapshot
24.13.2. Interview Transcript: Sukumar Sakamuri, Vice President and Head of Chemistry
24.14. Synaffix
24.14.1. Company Snapshot
24.14.2. Interview Transcript: Anthony DeBoer, Director, Business Development
24.15. Pierre Fabre
24.15.1. Company Snapshot
24.15.2. Interview Transcript: Christian Bailly, Director of CDMO
24.16. Catalent Pharma Solutions
24.16.1. Company Snapshot
24.16.2. Interview Transcript: Jennifer L. Mitcham, Director, SMARTag ADCs and Bioconjugates and Stacy McDonald, Group Product Manager
24.17. Lonza
24.17.1. Company Snapshot
24.17.2. Interview Transcript: Laurent Ducry, Head of Bioconjugates Commercial Development
24.18. Piramal Healthcare
24.18.1. Company Snapshot
24.18.2. Interview Transcript: Mark Wright, Site Head
24.19. Ajinomoto Bio-Pharma Services
24.19.1. Company Snapshot
24.19.2. Interview Transcript: Tatsuya Okuzumi, Associate General Manager
24.20. Cardiff University
24.20.1. Company Snapshot
24.20.2. Interview Transcript: Alan Burnett, Professor, School of Medicine
24.21. Anonymous, Chief Executive Officer, a Leading CMO
24.22. Anonymous, Director, Business Development, Leading CMO


Companies Mentioned

  • 3SBio
  • 3W Partners
  • 4BIO Capital
  • 5AM Ventures
  • 6 Dimensions Capital
  • AbbVie
  • ABL Bio
  • AbTis
  • Actinium Pharmaceuticals (ATNM)
  • Acuta Capital Partners
  • Adage Capital Management
  • Adagene
  • ADC Therapeutics
  • Adcendo
  • Advanced Proteome Therapeutics
  • Advantech
  • Agensys
  • Ajinomoto Bio-Pharma
  • Ally Bridge Group
  • Alphamab Oncology
  • Alta Partners
  • Alteogen
  • AltruBio
  • Ambrx
  • Amgen
  • Amgen Ventures
  • Angiex
  • Antikor Biopharma
  • Apricot Capital
  • Aravis
  • ARCH Venture Partners
  • Arix Bioscience
  • Arrowpoint Partners
  • Asana BioSciences
  • Astellas Pharma
  • AstraZeneca
  • Auven Therapeutics
  • Avacta
  • Avalon Ventures
  • AVICT Global
  • Avipep Therapeutics
  • Bayer
  • Bayern Kapital
  • BDC Capital
  • Beam Therapeutics
  • BeiGene
  • BioAtla
  • BioGeneration Ventures (BGV)
  • BioMed Valley Discoveries
  • BioMedPartners
  • Biotest
  • BlackRock
  • BlinkBio
  • Boehringer Ingelheim 
  • Boehringer Ingelheim Venture Fund
  • BOM Capital
  • Boxer Capital
  • Boyu Capital
  • Bregua
  • BrickBio
  • BrightGene Bio-Medical Technology
  • Bristol-Myers Squibb
  • btov Partners
  • BVF Partners
  • Byondis
  • Calculus Capital
  • California Institute for Regenerative Medicine (CIRM)
  • Cambridge Enterprise, University of Cambridge
  • Canaan Partners
  • Cancer Prevention and Research Institute of Texas (CPRIT)
  • Cancer Research Technology (CRT)
  • Cancer Research UK
  • Casdin Capital
  • Catalent
  • Catalent Biologics
  • CEL Healthcare
  • Celgene
  • Cellerant Therapeutics
  • Celltrion
  • Centre for the Commercialization of Antibodies and Biologics (CCAB)
  • Centrose
  • Changjinboya
  • Chengcheng Capital
  • Chiesi Ventures
  • Children’s Hospital Los Angeles
  • China Life Private Equity Investment
  • China Venture Capital Fund (CVC)
  • CITIC Private Equity (CPE) 
  • Clovis Oncology
  • Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator     (CARB-X)
  • Coparion
  • Cormorant Asset Management
  • Crescendo Biologics
  • CStone Pharmaceuticals
  • CTI Life Sciences Fund
  • CureMeta
  • CytomX Therapeutics
  • Daiichi Sankyo
  • Debiopharm
  • Decheng Capital
  • Deerfield Management
  • Diatheva
  • dievini Hopp BioTech
  • Efung Capital
  • EirGenix
  • Eli Lilly
  • EMD Serono
  • Esperance Pharmaceuticals
  • Essex Bio-Technology
  • Eurostars
  • Eventide
  • Everest Medicines
  • Exelixis
  • Farallon Capital
  • Femtogenix 
  • Fidelity Investments
  • Five Prime Therapeutics
  • Florida Institute of Technology
  • Fonds de solidarité FTQ
  • Foresite Capital
  • Fortis Therapeutics
  • Fosun Pharma (formerly Shanghai Fosun Pharmaceutical)
  • Freenome
  • GamaMabs Pharma
  • Genentech
  • GeneQuantum Healthcare
  • General Insurance Corporation of India (GIC)
  • Genmab
  • Genor Biopharma
  • GIC
  • Gilde Healthcare
  • Gilead Sciences
  • GlaxoSmithKline
  • Global Bio-India
  • Glycotope
  • Glykos
  • Glythera
  • Goodwin Biotechnology
  • Greater Bay Area Fund
  • GT Biopharma
  • Guotai Venture Capital
  • Gustave Roussy
  • Hangzhou DAC Biotech
  • Harbour BioMed
  • HBM Healthcare Investments
  • HealthCap
  • Heidelberg Pharma
  • Hercules Capital
  • Heritage Provider Network
  • High-Tech Gründerfonds
  • Hillhouse Capital
  • Hisun Pharmaceuticals
  • Hofon Capital
  • Sichuan Hongbo Equity Investment Fund Management
  • HOPU Investments
  • Huadong Medicine
  • Huagai Capital
  • Hudson Bay Capital Management
  • Humanwell Healthcare 
  • Iconic Therapeutics
  • Iksuda Therapeutics
  • ImmuneOncia Therapeutics
  • ImmunoBiochem
  • ImmunoGen
  • Immunome
  • Immunomedics (acquired by Gilead Sciences)
  • Innate Pharma
  • Innovate UK
  • Invenra
  • Invus
  • IP Group
  • iProgen Biotech
  • Janchor Partners
  • Janus Henderson Investors
  • Jazz Pharmaceuticals
  • Jiangsu Hengrui Pharmaceuticals
  • JLABS 
  • Johnson & Johnson Innovation
  • Johnson Matthey
  • JT New Century
  • JX Partners
  • K2 Investment
  • Kairos Therapeutics
  • King Star Capital
  • Kite Pharma
  • KLUS Pharma
  • Lake Bleu Capital
  • Laurion Capital Management
  • Legend Capital
  • LegoChem Biosciences
  • Levena Biopharma
  • LifeSci Venture Partners
  • Lilly Asia Ventures (LAV)
  • Lilly Ventures
  • Logos Capital
  • Loyal Valley Capital
  • Lumira Capital
  • MAB Discovery
  • MabSpace Biosciences
  • MabVax
  • MacroGenics
  • Magenta Therapeutics
  • Matrix Capital Management
  • Mayo Clinic
  • MediaPharma
  • MedImmune (acquired by AstraZeneca)
  • Meltwind
  • Memorial Sloan Kettering Cancer Center
  • Menarini
  • Merck
  • Merck KGaA
  • Mersana Therapeutics
  • Millennium Pharmaceuticals
  • MilliporeSigma
  • Minomic
  • Shanghai Miracogen
  • Mitsubishi Tanabe Pharma
  • Morphotek (Eisai)
  • MS Ventures
  • Multiple Myeloma Research Foundation (MMRF)
  • Myeloma Investment Fund
  • NanoValent Pharmaceuticals
  • National Cancer Institute (NCI)
  • National Research Council of Canada (NRC)
  • Navrogen
  • NBE-Therapeutics
  • Nerviano Medical Sciences
  • New Enterprise Associates
  • Nexthera Capital
  • Nordic Nanovector
  • Northeast Securities Prosperity Healthcare Fund
  • NovImmune
  • Novo Holdings
  • NovoCodex Biopharmaceuticals
  • o2h Ventures
  • OBI Pharma
  • OGD2 Pharma
  • Oncolinx
  • Oncomatryx Biopharma
  • OPKO Health
  • OrbiMed Advisors
  • Oriza Seed Venture Capital
  • Osage University Partners
  • Otsuka Pharmaceutical
  • Overland ADCT BioPharma
  • Oxford BioTherapeutics (OBT) 
  • Oxford Finance
  • PAG
  • Pappas Capital
  • Perceptive Advisors
  • Pfizer
  • Pfizer Ventures
  • pH Pharma
  • PharmAbcine
  • PharmaMar
  • Philogen
  • PICC Capital Equity Investment
  • Pierre Fabre
  • PolyTherics
  • PPF Capital Partners Fund
  • Puma Biotechnology
  • Pureos Bioventures
  • Pyxis
  • Pyxis Oncology
  • Qiming Venture Partners
  • Quantum Leap
  • RA Capital Management
  • Rakuten
  • Rakuten Medical
  • Ramot
  • Recepta Biopharma
  • Redalpine
  • Redmile Group
  • Redwood BioScience
  • Regeneron Pharmaceuticals
  • RemeGen
  • The Research Council of Norway
  • Ridgeback Capital Investments
  • Roche
  • Roche Venture Fund
  • Rock Springs Capital
  • RTW Investments
  • Samsara BioCapital
  • Samsung Biologics
  • Sanofi
  • Sarah Cannon Research Institute
  • SBI Group
  • Schroder Adveq (acquired by Schroders)
  • Seagen
  • Sequoia Capital China
  • Seventure Partners
  • Shanghai Pharmaceuticals
  • Shengda Group
  • Shenogen Pharma
  • Siamab Therapeutics
  • Silicon Valley Bank
  • Sinopharm Capital
  • SK
  • Skyline Ventures
  • Sofinnova Ventures
  • Soleus Capital
  • Sorrento Therapeutics
  • Springworks
  • Starling Ventures
  • Start Codon
  • Stonebridge Capital
  • Surveyor Capital
  • Sutro Biopharma
  • Suvretta Capital Management
  • Suzhou Wuzhong Biomedicine Industrial Park Investment
  • SV Health Investors
  • Synaffix
  • SyndicateRoom
  • Syndivia
  • Synthon
  • T. Rowe Price Associates
  • Taikang Insurance Group
  • Takeda Oncology
  • Takeda Pharmaceutical
  • Takeda Ventures
  • Tekla Capital Management
  • Terra Magnum Capital Partners (TMCP)
  • TF Capital
  • The Column Group
  • The Scripps Research Institute
  • Third Rock Ventures
  • TRIO Pharmaceuticals
  • Triphase Accelerator
  • Tubulis
  • UCB
  • University of Copenhagen
  • University of Wisconsin Carbone Cancer Center (UWCCC) 
  • Vaccinex
  • VelosBio (acquired by Merck)
  • Venrock Healthcare Capital Partners
  • Vertex Ventures
  • VI Partners
  • Vida Ventures
  • Viking Global Investors
  • Vir Biotechnology
  • Visterra
  • Vivo Capital
  • Wellington Management
  • WILD Family Office
  • Wild Ventures
  • WS Investments
  • WuXi AppTec (formerly known as WuXi PharmaTech)
  • WuXi Biologics
  • WuXi Healthcare Ventures
  • WuXi STA
  • Xintela
  • Y-Biologics
  • York University
  • Ysios Capital
  • Yuanda China
  • Yuhan Corporation
  • Yunfeng Capital
  • Zhejiang Teruisi Pharmaceutical
  • Zhejiang University Future Capital
  • Zheshang Venture Capital
  • Zymeworks